OncoGenex outlines plans for $48 million IPO

Canada's OncoGenex Technologies plans to raise up to $48 million in an IPO. The biotech has three products in development to inhibit the production of proteins linked to the resistance of treatments. The drug developer was founded in 2000 and has raised $35 million in venture capital. RBC Capital Markets will be the sole lead manager for the offering, and Needham & Company, Lazard Capital Markets, Canaccord Adams, and Susquehanna Financial Group are the co-managers.

- see this press release on the IPO
- here's the report from TechFinance.ca

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.